Innovative therapeutics for better lives

We are breaking the boundaries of standard therapeutic approaches. Our drug candidates aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema

Read more

A new approach to tackling Parkinson’s disease

Our novel drug candidate CDNF has the potential to stop the progression of Parkinson’s disease by protecting neurons from degeneration and by restoring their functions.

Learn more

Developing the first therapeutic treatment for secondary Lymphedema

Lymfactin® aims at being the first curative treatment of secondary lymphedema caused by injuries of the lymphatic system.

Learn more

Herantis’ Public Offering in Sweden and Denmark 18.11.-1.12.2019

Read more

Latest news and releases

Herantis on Twitter

Blog posts